Wet Age Related Macular Degeneration

Wet AMD occurs when abnormal blood vessels grow under the retina and leak causing vision loss.

What is wet macular degeneration?

Wet macular degeneration occurs when abnormal blood vessels (known as choroidal neovascularization) grow under the macula. These new blood vessels may then bleed and leak fluid, causing the macula to bulge or lift up from its normally flat position, thus distorting or destroying central vision. It is called wet because of the fluid the leaks from the abnormal blood vessels. Patient with wet macular degeneration usually develop rapid vision loss over the course of weeks or months. Straight lines may look wavy because the macula is no longer smooth. Below is a discussion of various manifestations of wet AMD. Click the button to learn more about the treament of wet AMD

Treatment of Wet AMD

What is a Choroidal Neovascular membrane?

Choroidal neovascular membranes are new blood vessels that grow beneath the retina and disrupt vision. These blood vessels grow in an area called the choroid, the area between the retina and the sclera (the white part of your eye). The choroid supplies oxygen and nutrients to the eye. These blood vessel growths break through the barrier between the choroid and the retina. Although one would think that more blood vessels supplying nutrients to the eye would be good, it is not. The new blood vessels grow out with scarring. Also, they leak more than normal retinal blood vessels. Finally they can bleed and blood is very harmful to the retina. Rarely patient maintain good vision with choroidal neovascular membranes (about 10 or 20 percent). Most people lose central vision rapidly who develop choroidal neovascular membranes unless they are treated.

What is a Disciform Scar?

Untreated, a person with a choroidal neovascular membrane will usually develop a submacular scar like the one in the photo. The scars are white because the are composed mostly of fibroblasts. Subretinal scars cause degeneration of the overlying retina and loss of vision. The scars are circular or disc shaped and therefore are called disciform scars. They cause vision loss because they block the transport of nutrients from the supporting tissue under the retina (the retinal pigment epithelium) which is vital to the survival and function of the retina. Unfortunately, once the retina has been permanently damaged by a submacular scar it cannot be resurrected. Retinal tissue does not regenerate. It cannot be replaced. Research is being pursued all over the world trying to find a way to fix damaged retinas, but nothing, at the moment (January 2015) is close to being effective.

What is Subretinal Fluid?

A hallmark of wet AMD is subretinal fluid. This comes from leaking abnormal blood vessels under the macula. Their is not a firm attachment between the retina and the underlying retinal pigment epithelium. The retina is held in place against the underlying retinal pigment epithelium by a pump in the retinal pigment epithelium. This pump removes naturally occurring fluid in the subretinal space and keeps it dry. The leakage from a choroidal neovascular membrane overwhelms the natural pump in the retinal pigment epithelium and subretinal fluid accumulates. The subretinal fluid distorts the retina causing patients to see things as wavy instead of straight. It also decreases the supply of oxygen and nutrients to the retina and makes the vision blurry. Subretinal fluid is best dectected using optical coherence tomography. The photo shows a dark area under the retina where subretinal fluid has accumulated. The effect (or lack of effect) of treatments for wet macular degeneration is usually evaluated by monitoring the optical coherence tomography scan for subretinal fluid.

What is a Pigment Epithelial Detachment?

Most patients with wet AMD develop a retinal pigment epithelial detachment. The retinal pigment epithelium is a layer of cells under the retina that supports the retina. In the OCT image it is the bright white line closest to the bottom of the picture with RPE on top of it. (there are two lines, the line on the bottom is the RPE, the line on the top is the back of the retina). When fluid or lipid (fatty material) or blood vessels accumulates under the retinal pigment epithelium the retinal pigment epithelium is pushed up. The bump in the retinal pigment epithelium is called a pigment epithelial detachment. These are common in wet AMD. Treatment does not always cause the retinal pigment epithelial detachment to flatten. Vision can be excellent over a retinal pigment epithelial detachment. The distortion of the overlying retina will often cause distortion in the vision. Retinal pigment epithlial detachments do not compromise the ability of the retinal pigment epithelium to nurish the retina. Finally, you can develop a retinal pigment epithelial detachment without wet AMD. These retinal pigment epithelial detachments have lipid (fatty) material in them but no blood vessels. About 90 percent of retinal pigment epithelial detachments are associated with wet AMD and abnormal blood vessel growth.

What is a Polypoidal Choroidal Vasculopathy (PCV)?

Polypoidal choroidal vasculopathy is a subtype of wet AMD that is caused by a mature vascular complex under the retina. It is characterized by a branching vascular network with one or more polyps at the termini of the vessels. The branching vascular network and the polyp(s) are best seen with indocyanine green angiography. There is some evidence the polypoidal choroidal vasculaopathy (PCV) is less response to anti-VEGF injection therapy than other forms of wet AMD. In many cases photodynamic therapy is helpful in treating PCV.

What is a Submacular Hemorrhage (Blood)?

Submacular hemorrhage (blood) is one of the most feared complications of wet AMD. The blood is toxic to the overlying retina and causes immediate severe vision loss. The photo shows blood in a patient whose vision dropped from 20/30 immediately to 20/1600 (no longer able to see even the big letters on the visual acuity chart). Fortunately, submacular hemorrhage is rare and occurs in only about 1 percent of patient with wet AMD. Once there is a submacular hemorrhage, vision almost never returns to what it was before the bleed. Treatment of wet AMD helps reduce the amount of vision loss. Surgery for submacular hemorrhage is controversial and may not be helpful. Visual recovery in someone with a submacular hemorrhage is very very slow. It usually takes about 6 months for the blood to absorb and then another 6-12 months for the overlying retina to heal. Vision usually improves some as the blood absorbs but not much. Most patients recover enough vision to see the big letters on the visual acuity chart but not enough vision to read.

Wet Macular Degeneration NEWS

Below are current articles from a Google News Feed on Wet Macular Degeneration

RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration  Yahoo Finance

TOKYO-- -- RBM-007 was well-tolerated with no dose-limiting toxicities, no systemic or ocular serious adverse events. Seven out of nine subjects showed ...

Implanted drug 'reservoir' safely reduces injections for people with macular degeneration  EurekAlert

In a clinical trial of 220 people with 'wet' age-related macular degeneration, Johns Hopkins Medicine researchers, collaborators from many sites across the ...

Adverum begins next step of wet AMD gene therapy trial  Healio

Dosing has started in the second cohort of an ongoing phase 1 clinical trial of gene therapy candidate ADVM-022 for the treatment of wet age-related macular ...

New implant technology safely minimizes injections for people with macular degeneration  News-Medical.net

In a clinical trial of 220 people with “wet” age-related macular degeneration, Johns Hopkins Medicine researchers, collaborators from many sites across the ...

FDA partially lifts clinical hold for Adverum's wet AMD gene therapy  Healio

The FDA has partially lifted the clinical hold on Adverum Biotechnologies' wet age-related macular degeneration gene therapy treatment candidate ADVM-022, ...

Adverum Biotechnologies Doses First Patient in Second Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Gene Therapy for Wet AMD  GlobeNewswire

... -- Continued Progress in the OPTIC Phase 1 Clinical Trial. -- Patients Receiving Single Intravitreal Injection of ADVM-022 Dosed at 2 x 10^11 vg/eye. MENLO ...

OliX confident of its age-related macular degeneration treatment's efficacy  Korea Biomedical Review

OliX Pharmaceutical said it plans to submit an investigational new drug application for OLX301A, a dry and wet age-related macular degeneration (AMD) ...

A Local Ophthalmologist Uses New Technology to Restore Vision in Patients With Dry Macular Degeneration  Sarasota

In the 1970s TV show, “The Six-Million-Dollar Man,” Steve Austin had, among his many super-human implements, a bionic eye with a tiny telescope to enhance ...

Age Related Macular Degeneration 2019 Global Market Size, Share, Emerging Trends, Sales Revenue, Key Players Analysis, Opportunity Assessment and Regional Forecast to 2023 |  Medgadget

As per the study offered by Market Research Future (MRFR), the global age related macular degeneration market is set to expand at a CAGR of 8.3% during.

BLOG: Suggestions for retina patients undergoing cataract surgery  Healio

Optometry Blogs | Alldredge Brooks | Previously, we discussed some general principles when considering cataract surgery in patients with retinal disease.

Outlook Is The One To Watch After Latest Advancements For Wet-AMD Treatment  Seeking Alpha

Outlook Therapeutics obtains clearance from FDA to initiate a second phase 3 study using its drug ONS-5010 to treat patients with wet age-related macular ...

Global Wet Age-Related Macular Degeneration Clinical Trial Pipeline Highlights 2019 - Forecast to 2024 - ResearchAndMarkets.com  Business Wire

DUBLIN--(BUSINESS WIRE)--The "Global Wet Age-Related Macular Degeneration Clinical Trial Pipeline Highlights - 2019" report has been added to ...

Global Ocular Implant Market to Surpass US$ 20.2 Billion by 2026  PRNewswire

SEATTLE, June 17, 2019 /PRNewswire/ -- According to Coherent Market Insights, the global ocular implant market was valued at US$ 11,697.9 million in 2018, ...

Province to continue allowing macular degeneration injections despite glaucoma fears  CBC.ca

The government of B.C. says injecting a drug into people's eyes to stave off blindness is safe and will continue despite the need for glaucoma surgery in some ...

Macular Degeneration (AMD) and Diabetic Retinopathy (DR) Drugs Market to Expand Substantially Owing to Technological Innovations During 2015 – 2021  Kentucky Journal 24

Age related macular degeneration (AMD) is a medical condition that results in loss of vision in the central visual field, owing to damage to the retina. This is ...

Recon: Pfizer to Acquire Array Biopharma for $11.4B  Regulatory Focus

Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence briefing. In Focus: US. Pfizer to boost cancer treatment portfolio with ...

Healthy Living June 4, 2019  WABI

BANGOR, Maine (WABI) - Wet macular degeneration the leading cause of visual loss in the elderly population of the United States can be complicated by ...

REGENXBIO completes dosing in mid-stage wet AMD study  Seeking Alpha

REGENXBIO (RGNX) has completed dosing across all five cohorts in the Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration.

Business Outline of Wet Macular Degeneration and Investment Breakdown, Insights, Scope, Forecast by 2024  The Scripps Voice

Wet Macular Degeneration Market report covers the disease overview, definition, classification, symptoms, ethology, pathophysiology and diagnostic methods.

Outlook Therapeutics stock triples in three days after Oppenheimer offers $12 price target  Proactive Investors USA & Canada

Outlook Therapeutics (NASDAQ:OTLK) - Analysts at Oppenheimer saw potential in the development of its ONS-5010 treatment for various eye diseases.

Treatment for Wet Age-Related Macular Degeneration Receives Biologics License Application Approval  Pharmacy Times

Officials with the FDA have accepted Novartis' Biologics License Application (BLA) for brolucizumab (RTH258), a humanized single-chain antibody fragment ...

Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting  BioSpace

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, ...

'Eye-in-a-dish' model helps scientists to uncover 'surprising' AMD gene variant  News-Medical.net

Researchers have discovered a new genetic variant responsible for blood vessel dysregulation in the development of age-related macular degeneration (AMD).

Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010  GlobeNewswire

CRANBURY, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical ...

What you need to know about wet macular degeneration Feb 14, 2019  Medical Xpress

Millions of people deal with age-related macular degeneration as they get older, but many don't understand the difference between types of the condition or ...

What Is the Difference Between Wet or Dry Macular Degeneration?  University of Michigan Health System News

A Michigan Medicine eye specialist explains the signs and symptoms of each type of age-related macular degeneration — and how your doctor can help.

Fewer Injections With New Wet Macular Degeneration Therapies  Medscape

New treatments in development — including gene therapy — will likely mean fewer injections for patients with neovascular age-related macular degeneration, ...

Age-related Macular Degeneration Treatment Technology Market to Expand at a Robust CAGR by 2025  Market Reporter

Age-related macular degeneration (AMD) is a health issue associated with the retina. According to the National Medical Research Council (Singapore), ...

Age-related Macular Degeneration Market Pegged for Robust Expansion by 2025  Market Reporter

Age-Related Macular Degeneration is also called macular degeneration, ARMD, or AMD. AMD is a disease of retina that blurs the sharp central vision, which is ...

First patient dosed in Ocular Therapeutix wet AMD trial  Healio

The first patient has been dosed in a phase 1 clinical trial of OTX-TKI for patients with wet age-related macular degeneration, according to a press release from ...

Re-Vana Therapeutics Names Renowned International Experts to Inaugural Scientific Advisory Board  BioSpace

New International Team Brings Extensive Ocular Drug Delivery and Scientific Expertise to Advance the Sustained Release of Biologics and Small Molecules into ...

Age-Related Macular Degeneration Competitive Landscape to 2026: Key Trends, Innovative products and Technologies  Automobile Posts

Age-Related macular degeneration (AMD) is one of the leading cause of vision loss among people ages 50 and over in the developed world, characterized by ...

TRACON Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference  Yahoo Finance

SAN DIEGO, May 30, 2019 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and ...

7 Tips to Stop Macular Degeneration  Healthline

Macular degeneration is one of the leading causes of blindness in the United States. Here's how to keep your vision safe while enjoying the sun this spring ...

Age-Related Macular Degeneration: 5 Things to Know  Medscape

A guide to the latest on this chronic disease, from emerging treatments to the risk factors to be on the lookout for.

Trial will be first in US of Nobel-winning stem cell technique  STAT

Curing diabetes with stem cells? Everyone knew that would be hard. Parkinson's disease? Harder. Alzheimer's? Probably impossible. But age-related macular ...

Role of immune cells in macular scarring development explored OT  AOP

Research funded by Fight for Sight is being carried out by Queen's University Belfast.

What Is Age-Related Macular Degeneration?  Next Avenue

Age-related macular degeneration (AMD) causes deterioration of the macula, the part of the eye that provides sharp, clear, straight-ahead vision. As many Here ...

Cellectis S.A. (CLLS) and Clearside Biomedical Inc. (NASDAQ:CLSD) Comparison side by side  Stocks Beat

This is a contrast between Cellectis S.A. (NASDAQ:CLLS) and Clearside Biomedical Inc. (NASDAQ:CLSD) based on their institutional ownership, earnings and.

Vitamins, new treatments offer hope for people with macular degeneration  nwitimes.com

Macular degeneration is the leading cause of vision loss, affecting more than 10 million Americans — more than cataracts and glaucoma combined.

Global Age Related Macular Degeneration (AMD) Market Size, Experiments, Research, Analysis, Evolutions and Forecast 2019-2025  Market Reporter

This research report titled Global Age Related Macular Degeneration (AMD) Market Size, Status and Forecast 2019-2025 has been added to the wide online ...

Kodiak Sciences to Present at the Jefferies 2019 Healthcare Conference  PRNewswire

PALO ALTO, Calif., May 30, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel ...

Technological advances, preventable strategies can help manage age-related macular degeneration  Reading Eagle

Age-related macular degeneration, or AMD, has long been a scourge for many people as they age.

Wet Age-Related Macular Degeneration Market to Reach $10.4 Billion by 2024: P&S Intelligence  GlobeNewswire

NEW YORK, March 11, 2019 (GLOBE NEWSWIRE) -- According to the market research report published by P&S Intelligence, global wet age-related macular ...

Macular Degeneration Treatment Market to Reach Approximately US$ 11.1 Bn by 2026  Amazing Newspaper

Transparency Market Research (TMR) has published a new report titled “Macular degeneration treatment Market – Global Industry Analysis, Size, Share, Growth ...

Take steps to prevent vision loss from macular degeneration  Buffalo News

By Judith Whitehead – Contributing Writer Age-related macular degeneration is the leading cause of blindness among older Americans but treatments have ...

VIDEO: Oral treatment shows good visual improvement in newly diagnosed wet AMD patients  Healio

FORT LAUDERDALE, Fla. — At the Retina World Congress, Michael W. Stewart, MD, professor and chairman of ophthalmology at the Mayo Clinic in ...

Novel anti-VEGF for wet AMD meets safety, tolerability endpoint  Healio

WAIKOLOA, Hawaii — Sunitinib, a novel intravitreal anti-VEGF delivered via a biodegradable depot for extended treatment of neovascular age-related macular ...

Global $10.4 Bn Wet Age-Related Macular Degeneration Market to 2024 - Rising Prevalence of AMD, Lack of a Specific Treatment, and Increasing Aging Population  GlobeNewswire

Dublin, May 15, 2019 (GLOBE NEWSWIRE) -- The "Wet Age-Related Macular Degeneration Market by Product, by Distribution Channel, by Age Group, by ...

First patient dosed in Innovent wet AMD trial  Healio

Innovent Biologics has dosed the first patient in a phase 1 trial of IBI302, the company's wet age-related macular degeneration treatment candidate, according to ...

Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN  Yahoo Finance

It was a busy week for the biotech sector. While leading biotech Celgene Corporation CELG obtained EC approval for label expansion of its drugs, ImmunoGen ...

Biologics license application accepted for brolucizumab for wet AMD  Healio

The FDA has accepted a biologics license application for brolucizumab for the treatment of neovascular age-related macular degeneration, Novartis announced ...

Regeneron Pharmaceuticals, Inc. - Consenus Indicates Potential 27.5% Upside  DirectorsTalk Interviews

Regeneron Pharmaceuticals, Inc. found using ticker (REGN) have now 21 analysts covering the stock with the consensus suggesting a rating of 'Buy'. The.

Contrasting of Trevi Therapeutics Inc. (TRVI) and Clearside Biomedical Inc. (NASDAQ:CLSD)  Stocks Beat

This is therefore a comparing of the profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation in Trevi Therapeutics ...

Contrasting of Kodiak Sciences Inc. (KOD) and Athersys Inc. (NASDAQ:ATHX)  Stocks Beat

We are contrasting Kodiak Sciences Inc. (NASDAQ:KOD) and Athersys Inc. (NASDAQ:ATHX) on their dividends, analyst recommendations, profitability, ...

FDA places clinical hold on IND application for Adverum's wet AMD gene therapy  Healio

The FDA has placed a clinical hold on Adverum Biotechnologies' investigational new drug application for its gene therapy candidate for wet age-related macular ...

Experimental drug delivers one-two punch to vision loss: Experiments show new therapy slows blood vessel leakage associated with diabetic macular edema and macular degeneration  Science Daily

In studies with lab-grown human cells and in mice, researchers have found that an experimental drug may be twice as good at fighting vision loss as previously ...

Two phase 3 trials to investigate faricimab for wet AMD  Healio

Roche and Genentech are initiating two phase 3 global trials to investigate the bispecific molecule faricimab for the treatment of wet age-related macular ...

Seeing clearly: Know your risk for macular degeneration  Baylor College of Medicine News

More than 60 million Americans are estimated to be at high risk for vision loss. However, according to the CDC, only half of those at risk have visited an eye ...

Comparing of TRACON Pharmaceuticals Inc. (TCON) and Trevena Inc. (NASDAQ:TRVN)  Stocks Beat

As Biotechnology businesses, TRACON Pharmaceuticals Inc. (NASDAQ:TCON) and Trevena Inc. (NASDAQ:TRVN), are affected by compare. This especially ...

7 Healthy Habits to Help Prevent Macular Degeneration  University of Michigan Health System News

AMD affects the eyesight of millions. A Michigan Medicine specialist offers easy ways to help slow or prevent the disease.

Reviewing Menlo Therapeutics Inc. (MNLO)'s and Clearside Biomedical Inc. (NASDAQ:CLSD)'s results  Stocks Beat

Menlo Therapeutics Inc. (NASDAQ:MNLO) and Clearside Biomedical Inc. (NASDAQ:CLSD), both competing one another are Biotechnology companies. We will ...

Global Wet Age Related Macular Degeneration (AMD) Market 2019-2025 Growth, Trends and Demands Research Report  MajoReports

The market study on the global Wet Age Related Macular Degeneration (AMD) market will encompass the entire ecosystem of the industry, covering five major ...

Macular Degeneration Treatment Market – Increase in Patient Population and Approval of New Products to Fuel the Market  Amazing Newspaper

The global macular degeneration treatment market was valued at US$ 6.1 Bn in 2017. It is anticipated to reach US$ 11.1 Bn by 2026, expanding at a CAGR of ...

REGENXBIO announces completion of phase I/IIA RGX-314 clinical trial  News by Intelligence Journal

Every subject received one dose of RGX-314 managed by subretinal delivery. The leading clinical-stage biotechnology company REGENXBIO Inc. has recently ...

Outlook up 22% premarket on manufacturing deal for ONS-5010  Seeking Alpha

Nano cap Outlook Therapeutics (OTLK) is up 22% premarket on robust volume on the heels of its agreement with FUJIFILM Diosynth Biotechnologies for the ...

Wet Macular Degeneration Market Clinical Analysis 2016  Market Research Periodical

Wet Macular Degeneration – Market Insight, Epidemiology and Market Forecast – 2028″ report provides a detailed analysis of the Wet Macular Degeneration ...

Human Trials Could Begin for Macular Degeneration Stem Cell Therapy  MD Magazine

FDA trial approval would make this trial the first ever to test a stem cell-based therapy derived from induced pluripotent stem cells for treating any disease.

With FDA Approval Of Zolgensma, Regenxbio Sets Out For First Revenue Stream  Seeking Alpha

Regenxbio expects to obtain royalty payments from Novartis for Zolgensma after it was approved by the FDA to treat patients with spinal muscular atrophy.

AMD Monitoring Comes Home: The Promise of Remote Tech  Medscape

Age-related macular degeneration (AMD) is the leading cause of severe vision loss in older Americans. AMD is a degenerative disease that affects the macula, ...

Macular degeneration treatment market size worth around US $11.4 billion by 2026: Acumen Research and Consulting  GlobeNewswire

LOS ANGELES, March 16, 2019 (GLOBE NEWSWIRE) -- The global macular degeneration treatment market size is anticipated to value USD 11.4 billion by ...

VIDEO: Wet AMD gene therapy trial shows optimistic results  Healio

VANCOUVER, British Columbia —Allen C. Ho, MD, of Wills Eye Hospital discusses phase 1/2 data from a clinical trial of a gene therapy treatment candidate for ...

Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration  Science Advances

Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade ...

Opthea's Phase 2b Trial in Wet AMD Advances with a Second Positive Independent Safety Committee Recommendation  GlobeNewswire

MELBOURNE, Australia, March 07, 2019 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT) is pleased to announce that the independent Data and Safety ...

Fresh insights into genes and macular degeneration could open new treatment pathways  FierceBiotech

NIH researchers have pinpointed 6 genomic regions that are closely associated with the development of age-related macular degeneration. (Pixabay).

Adverum Biotechnologies, Inc. (ADVM) Reaches $11.52 After 9.00% Up Move; Concho Resources Inc. (CXO) Covered By 10 Bullish Analysts Last Week  Stocks Beat

The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) is a huge mover today! The stock increased 6.47% or $0.7 during the last trading session, ...

Age Related Macular Degeneration Market Analysis Revealing Key Drivers, Growth Trends and Competitive Assessment through 2023  Market Research Gazette

As per the study offered by Market Research Future (MRFR), the global age related macular degeneration market is set to expand at a CAGR of 8.3% during the ...

RGX-314 Gene Therapy for Wet AMD Well Tolerated at 24 Weeks  MD Magazine

After a single dose of RGX gene therapy, the mean change in BCVA was +8 letters in cohort 3 and the average number of injections over the course of 6 months ...

Implantable Ranibizumab Port for Wet AMD Lasts Up to 15 Months  MD Magazine

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 ...

Implant Poised to Transform Macular Degeneration Treatment  Medscape

VANCOUVER, Canada — An experimental implant that delivers ranibizumab controls the progression of neovascular age-related macular degeneration as well ...

Eye's vulnerability to macular degeneration revealed  Medical Xpress

Scientists have found significant differences in the shape and biology of the same type of cell taken from different parts of the retina, according to a study in eLife.

How to spot age-related macular degeneration  The Guardian

Every day in the UK, nearly 200 people develop a condition that can lead to visual impairment or even blindness. How do you identify the symptoms and what's ...

Genprex Inc. (GNPX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS)  Stocks Beat

As Biotechnology businesses, Genprex Inc. (NASDAQ:GNPX) and Coherus BioSciences Inc. (NASDAQ:CHRS), are affected by contrast. This especially applies ...

Novartis' wet AMD drug gets FDA filing  PharmaTimes

Novartis has announced the US Food and Drug Administration (FDA) filing acceptance and priority review of its wet AMD drug, RTH258 (brolucizumab).

Stem Cell Therapy Patch for Macular Degeneration Sees the Light of Day  Genetic Engineering & Biotechnology News

If approved, the first ever clinical trail to test a stem cell-based therapy may provide a cure for age-related macular degeneration.

Adverum Announces First Patient Dosed in OPTIC Phase 1 Trial of ADVM-022 Gene Therapy in Wet Age-Related Macular Degeneration  GlobeNewswire

ADVM-022 is the first intravitreally delivered gene therapy utilizing directed evolution AAV.7m8 vector for wet AMD; OPTIC trial to evaluate single administration ...

Revolutionary eye drops to treat age-related macular degeneration  Drug Target Review

Revolutionary eye drops to treat age-related macular degeneration - developing an eye drop that could revolutionise treatment for AMD.

Wet Macular Degeneration Pipeline Insight – 2019 Analysis with Research Report  Market Research Periodical

Latest Industry Research Report On “Wet Macular Degeneration – Pipeline Insight, 2019” in-depth analysis of the market state and also the competitive ...

7 Macular Degeneration Risk Factors You Can Control—and 4 You Can't  Reader's Digest

Your chances of getting this top cause of vision loss in people age 60 and older—depends on both your genetics and your lifestyle.

First patient dosed in Adverum wet AMD gene therapy trial  Healio

The first patient has been dosed in a phase 1 trial of ADVM-022 gene therapy for wet age-related macular degeneration, Adverum Biotechnologies announced ...

Alkahest to Present Results from Phase 2a Open Label Study of AKST4290 in wet AMD at Retina World Congress  BioSpace

Published: Mar 14, 2019. SAN CARLOS, Calif., March 14, 2019 /PRNewswire/ -- Alkahest, Inc., a clinical stage biotechnology company focused on developing ...

Days of our Lives Star Deidre Hall Wants to Help Prevent Blindness from Wet AMD  Parade

Deidre Hall isn't really a doctor; she just plays one on TV. But now the actress, who has played Dr. Marlena Evans on Days of our Lives since 1976, is speaking ...

Anti-VEGF Agents better than no Anti-VEGF agents for AMD Patients  MD Magazine

Investigators from Johns Hopkins examined 16 RCTs to determine efficacy of three anti-VEGF agents for patients with neovascular age-related macular ...

Regenxbio completes dosing in phase 1 trial of gene therapy for wet AMD  Healio

Dosing is complete in a phase 1 clinical trial of RGX-314, a gene therapy treatment for wet age-related macular degeneration, according to a press release from ...

Adverum Biotechnologies to Present 30-month Preclinical Safety and Expression Data for ADVM-022 Gene Therapy in Wet AMD at the ASGCT 22nd Annual Meeting  Associated Press

Press release *content* from Globe Newswire. The AP news staff was not involved in its creation.

Surgeons perform first gene therapy procedure aimed at stopping AMD-related blindness  Healio

Researchers have completed the first gene therapy procedure aimed at stopping age-related macular degeneration.The operation was performed at John ...

Macular Degeneration Patient Visual Hallucinations Associated with Retina  MD Magazine

The effects of Charles Bonnet Syndrome have been fairly documented, yet its pathology has been minimally assessed.

Neptune Wellness Solutions Inc. (NEPT) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Comparison side by side  Stocks Beat

Both Neptune Wellness Solutions Inc. (NASDAQ:NEPT) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON) compete on a level playing field in the ...

Roche's Faricimab Shows Long-Term Durability in Macular Degeneration  BioSpace

Roche announced positive data from its Phase II STAIRWAY clinical trial. The trial evaluated the extended durability of faricimab (RG7716) in the treatment of ...

Eye implant could more effectively prevent a common form of blindness  New Atlas

Age-related macular degeneration (AMD) is one of the leading causes of blindness in older people, with the "wet" form of the disease being responsible for ...

» Load more

What about Resources?

Dr. Pautler's Blog
American Academy of Ophthalmology
MedlinePlus
National Institutes of Health
  • ARMD
    NIH's SeniorHealth website covers the topic of Age-Related Macular Degeneration
National Eye Institute
American Foundation for the Blind - Senior Site
  • Macular Degeneration
    Basic information about AMD and low vision; includes a self-test using an Amsler Grid
Journal of the American Medical Association (JAMA)
WebMD
LightHouse International
  • Macular Degeneration
    Provides a general overview of the basics of AMD, and a simulation showing a scene as it might be viewed by a person with AMD
Prevent Blindness America